Howard Feldman mainly investigates Disease, Dementia, Psychiatry, Alzheimer's disease and Frontotemporal lobar degeneration. The Disease study combines topics in areas such as Clinical trial, Gerontology, Intensive care medicine and Neuroimaging, Neuroscience. His studies in Dementia integrate themes in fields like Developmental psychology, Pediatrics and MEDLINE.
His Psychiatry research incorporates themes from Dementia with Lewy bodies, REM sleep behavior disorder and Cognitive decline. His Frontotemporal lobar degeneration study incorporates themes from SNP, Genetics, Neuropathology and C9orf72. His studies deal with areas such as C9orf72 Protein, UBQLN2 and TARDBP as well as C9orf72.
His primary scientific interests are in Dementia, Disease, Internal medicine, Alzheimer's disease and Psychiatry. Howard Feldman does research in Dementia, focusing on Frontotemporal dementia specifically. In general Frontotemporal dementia study, his work on Frontotemporal lobar degeneration often relates to the realm of Cytoplasmic inclusion, thereby connecting several areas of interest.
His Frontotemporal lobar degeneration research includes themes of Mutation, C9orf72 and Genetics. His Disease study combines topics from a wide range of disciplines, such as Clinical trial, Neuroscience, MEDLINE and Intensive care medicine. His Alzheimer's disease research is multidisciplinary, relying on both Central nervous system disease, Degenerative disease, Dementia with Lewy bodies, Neuroimaging and Biomarker.
Howard Feldman focuses on Dementia, Disease, Clinical trial, Gerontology and Cognition. His work deals with themes such as Neuroscience and Cohort, which intersect with Dementia. His biological study spans a wide range of topics, including Psychological intervention and Neuroimaging.
His Clinical trial study integrates concerns from other disciplines, such as Frontotemporal dementia, Psychiatry, Intensive care medicine, Confounding and Repeated measures design. All of his Frontotemporal dementia and C9orf72 and Frontotemporal lobar degeneration investigations are sub-components of the entire Frontotemporal dementia study. His work carried out in the field of Cognition brings together such families of science as Percentile and Cognitive decline.
Howard Feldman mainly focuses on Dementia, Disease, Cohort, Gerontology and Clinical trial. The concepts of his Dementia study are interwoven with issues in Cognition and Neuroscience. In his study, which falls under the umbrella issue of Disease, Alzheimer's disease, Artificial intelligence and Pattern recognition is strongly linked to Neuroimaging.
His Cohort research integrates issues from Population ageing, Mild memory loss and Cohort study. The various areas that Howard Feldman examines in his Clinical trial study include Frontotemporal dementia, Intensive care medicine, Dosing, Apathy and Oxytocin. His C9orf72 study in the realm of Frontotemporal dementia interacts with subjects such as Subcortical gray matter.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis
Manuela Neumann;Deepak M. Sampathu;Linda K. Kwong;Adam C. Truax.
Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium
I. G. McKeith;I. G. McKeith;D. W. Dickson;J. Lowe;M. Emre.
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
Bruno Dubois;Howard H. Feldman;Claudia Jacova;Steven T. DeKosky.
Lancet Neurology (2007)
Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS
Mariely DeJesus-Hernandez;Ian R. Mackenzie;Bradley F. Boeve;Adam L. Boxer.
The Diagnosis of Mild Cognitive Impairment due to Alzheimer’s Disease: Recommendations from the National Institute on Aging-Alzheimer’s Association Workgroups on Diagnostic Guidelines for Alzheimer’s Disease
Marilyn S. Albert;Steven T. DeKosky;Dennis Dickson;Bruno Dubois.
Mild cognitive impairment
Serge Gauthier;Barry Reisberg;Michael Zaudig;Ronald C. Petersen.
The Lancet (2006)
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Bruno Dubois;Bruno Dubois;Howard H Feldman;Claudia Jacova;Harald Hampel;Harald Hampel.
Lancet Neurology (2014)
Revising the definition of Alzheimer's disease: a new lexicon.
Bruno Dubois;Howard H. Feldman;Howard H. Feldman;Howard H. Feldman;Claudia Jacova;Jeffrey L. Cummings.
Lancet Neurology (2010)
Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17
Matt Baker;Ian R. Mackenzie;Stuart M. Pickering-Brown;Jennifer Gass.
Diagnosis and management of dementia with Lewy bodies Fourth consensus report of the DLB Consortium
Ian G. McKeith;Bradley F. Boeve;Dennis W. DIckson;Glenda Halliday.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: